Pieniaszek, Henry J <br/><br/>
Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.  [electronic resource] 

 -  Journal of clinical pharmacology  Jul 2002 
 - 738-53 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0091-2700 
<br/><br/><label>Standard No.: </label>10.1177/009127002401102687  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adolescent<br/>Adult<br/>Age Factors<br/>Aged<br/>Amidines--administration & dosage<br/>Amino Acids--blood<br/>Area Under Curve<br/>Aspirin--pharmacology<br/>Bleeding Time<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Interactions<br/>Female<br/>Humans<br/>Hydrolysis<br/>Isoxazoles--administration & dosage<br/>Male<br/>Middle Aged<br/>Platelet Aggregation Inhibitors--administration & dosage<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Prodrugs--administration & dosage<br/>Time Factors